What Can Investors Expect From Valeant Pharmaceuticals Intl Inc.?

Because of high debt, a money-losing partnership, and questions about whether or not insiders have faith, I say avoid Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) for now.

The Motley Fool

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) continues to confound investors, leaving them confused as to whether they should start buying shares, sell their positions, or just not think about it. Between talk about defaulting on debt, investors selling their shares, partnership problems, and new products launching, not knowing what to do can be quite unsettling.

Here’s what investors can expect from Valeant.

First, on the topic on debt, there’s no denying that Valeant is sitting on $30 billion in debt. In its quest to become one of the largest pharmaceutical companies on the market, it levered itself up significantly. However, there are only two ways that a business has to shut down, and that’s if management gives up or if it runs out of money. Fortunately, I don’t see that happening anytime soon.

If we look at its 10Q for the first quarter, there are conflicting numbers. If we look at its GAAP EPS, it saw a loss of $1.08 per share. Its non-GAAP adjusted earnings per share showed a positive $1.27. But what leaves me somewhat confident is that it had GAAP cash flow from operations of $558 million, up 14% year over year. So long as there is cash flow, Valeant should be able to make its debt payments.

Then there’s the fact that Sequoia Fund, Valeant’s second-largest shareholder, decided to get rid of its entire stake in the company. And Michael Pearson, the former CEO of Valeant, sold nearly US$100 million in shares of Valeant. When big investors and insiders start selling, it can be concerning. However, what’s important to pay attention to going forward is true insider acquisitions. If we see key employees buying shares, there’s confidence in the company.

Noted in the 10Q, management had to slash its earnings guidance to somewhere between $6.60 and $7.00 per share. This is down quite significantly from the $8.50-9.50 it had initially planned to make. One of the reasons is because of a distribution partnership it signed with Walgreens. During the call, CEO Joseph Papa said, “every time a prescription goes out the door [Walgreens’s door], we’re taping dollars bills to that prescription.” Valeant is losing money on this distribution deal.

The reason is because prior to the company revealing that it was increasing the price of its drugs significantly, it was able to generate lucrative earnings even with this deal. However, now that it has had to reduce prices, it can’t sustain it. What Valeant intends to do with this deal is still up in the air, but it could depress earnings for some time.

The good news for investors is that Valeant is expecting to get FDA approval for a few new drugs.

First, there’s Relistor oral, which treats opioid-induced constipation; Valeant expects to receive an answer in the next few days. Then there’s Vesneo, which treats elevated intraocular pressure. And finally, the Dermatologic and Ophthalmic Drugs Advisory Committee is meeting today to discuss brodalumab for treatment of moderate to severe plaque psoriasis in adults. One analysts believes brodalumab could generate US$400-500 million in peak U.S. sales if approved.

If this post leaves you scratching your head, that’s basically the point. Valeant could very well become a success again, and Joe Papa is definitely the executive to lead that charge. However, there are many uncertainties around its debt, its partnerships, and whether or not insiders are actually interested in it. Because of this, my advice is to avoid this stock. Come back when things get a little clearer.

Fool contributor Jacob Donnelly has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

oil pumps at sunset
Energy Stocks

How a $25,000 TFSA Could Fund Your Retirement

Canadians can turn to the TFSA to help provide a meaningful income stream in retirement.

Read more »

Canada day banner background design of flag
Investing

3 of the Best Canadian Stocks to Buy Right Now

These three Canadian stocks are ideal for balancing wealth-creation opportunities with stability and income generation in this uncertain outlook.

Read more »

Blocks conceptualizing Canada's Tax Free Savings Account
Dividend Stocks

TFSA Strategy: How to Earn $500 a Month in Tax-Free Dividend Income

Canadians can earn $500 in tax-free dividend income or another desired amount every month using a simple TFSA strategy.

Read more »

coins jump into piggy bank
Energy Stocks

Canadian Natural Resources vs. Enbridge: The Better Dividend Stock to Buy Today

Both CNQ and ENB have impressive payout records, consistently paying and increasing their dividends for decades.

Read more »

doctor uses telehealth
Dividend Stocks

TFSA Investors: This Monthly Dividend Stock Yields 7.6%

This REIT offers investors a monthly yield investors and a regular and frequent passive income stream to supplement their regular…

Read more »

shopper chooses vegetables at grocery store
Dividend Stocks

Loblaw vs. Empire: Which Grocery Stock Would I Choose for Long-Term Growth?

Both grocers benefit from repeat shoppers. I’d give Loblaw the edge for the ways it can earn more from those…

Read more »

Retirees sip their morning coffee outside.
Dividend Stocks

2 Canadian Stocks to Buy and Hold for 20 More Years

CP Rail (TSX:CP) and another outstanding Canadian stock that's more than worth holding for many decades.

Read more »

ETF is short for exchange traded fund, a popular investment choice for Canadians
Dividend Stocks

2 Top TSX ETFs to Buy and Hold in a TFSA Forever

Looking for top TSX ETFs for your TFSA? Explore how VFV and VDY combine U.S. stock exposure and Canadian dividends…

Read more »